File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis

TitleA comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis
Authors
KeywordsBronchiectasis
Ceftazidime
Exacerbations
Levofloxacin
Issue Date1999
PublisherEuropean Respiratory Society. The Journal's web site is located at http://erj.ersjournals.com
Citation
The European Respiratory Journal, 1999, v. 14 n. 5, p. 1206-1209 How to Cite?
AbstractA prospective randomized study was performed in order to compare the efficacy of oral levofloxacin, a new S- isomer of ofloxacin, with intravenous ceftazidime in the empirical treatment of acute exacerbations of bronchiectasis. Consecutive patients with acute exacerbation of bronchiectasis were recruited at a tertiary referral centre and were randomized to receive 10 days' treatment with either oral levofloxacin (300 mg b.i.d.) or ceftazidime (1 g i.v.t.i.d.). Body temperature, cough score, dyspnoea score, sputum purulence and volume and white blood cell and neutrophil count were assessed on day 1 and day 10. Thirty-five patients (mean age 61 yrs, 15 males) completed the study; 17 of these were in the levofloxacin group. There was no significant difference in the distribution of sputum pathogens or clinical parameters between the two groups at entry to and completion of the study. Both groups of patients showed significant improvement in 24-h sputum volume, sputum purulence score, cough score and dyspnoea score (p<0.001) but there was no significant difference between these two groups at entry to or on completion of the study (p>0.05). The results of this study suggest that oral administration of levofloxacin is as effective as parenteral ceftazidime in the empirical treatment of exacerbations in bronchiectasis.
Persistent Identifierhttp://hdl.handle.net/10722/157292
ISSN
2015 Impact Factor: 8.332
2015 SCImago Journal Rankings: 3.204
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTsang, KWTen_HK
dc.contributor.authorChan, WMen_HK
dc.contributor.authorHo, PLen_HK
dc.contributor.authorChan, Ken_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorIp, MSMen_HK
dc.date.accessioned2012-08-08T08:48:42Z-
dc.date.available2012-08-08T08:48:42Z-
dc.date.issued1999en_HK
dc.identifier.citationThe European Respiratory Journal, 1999, v. 14 n. 5, p. 1206-1209en_HK
dc.identifier.issn0903-1936en_HK
dc.identifier.urihttp://hdl.handle.net/10722/157292-
dc.description.abstractA prospective randomized study was performed in order to compare the efficacy of oral levofloxacin, a new S- isomer of ofloxacin, with intravenous ceftazidime in the empirical treatment of acute exacerbations of bronchiectasis. Consecutive patients with acute exacerbation of bronchiectasis were recruited at a tertiary referral centre and were randomized to receive 10 days' treatment with either oral levofloxacin (300 mg b.i.d.) or ceftazidime (1 g i.v.t.i.d.). Body temperature, cough score, dyspnoea score, sputum purulence and volume and white blood cell and neutrophil count were assessed on day 1 and day 10. Thirty-five patients (mean age 61 yrs, 15 males) completed the study; 17 of these were in the levofloxacin group. There was no significant difference in the distribution of sputum pathogens or clinical parameters between the two groups at entry to and completion of the study. Both groups of patients showed significant improvement in 24-h sputum volume, sputum purulence score, cough score and dyspnoea score (p<0.001) but there was no significant difference between these two groups at entry to or on completion of the study (p>0.05). The results of this study suggest that oral administration of levofloxacin is as effective as parenteral ceftazidime in the empirical treatment of exacerbations in bronchiectasis.en_HK
dc.languageengen_US
dc.publisherEuropean Respiratory Society. The Journal's web site is located at http://erj.ersjournals.comen_HK
dc.relation.ispartofThe European Respiratory Journalen_HK
dc.subjectBronchiectasisen_HK
dc.subjectCeftazidimeen_HK
dc.subjectExacerbationsen_HK
dc.subjectLevofloxacinen_HK
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAnti-Infective Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshBronchiectasis - Drug Therapyen_US
dc.subject.meshCeftazidime - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshCephalosporins - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intravenousen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOfloxacin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshProspective Studiesen_US
dc.titleA comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasisen_HK
dc.typeArticleen_HK
dc.identifier.emailHo, PL: plho@hkucc.hku.hken_HK
dc.identifier.emailChan, K: kaimin@hkucc.hku.hken_HK
dc.identifier.emailIp, MSM: msmip@hku.hken_HK
dc.identifier.authorityHo, PL=rp00406en_HK
dc.identifier.authorityChan, K=rp00489en_HK
dc.identifier.authorityIp, MSM=rp00347en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid10596714-
dc.identifier.scopuseid_2-s2.0-0032695688en_HK
dc.identifier.hkuros50547-
dc.identifier.hkuros49922-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032695688&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue5en_HK
dc.identifier.spage1206en_HK
dc.identifier.epage1209en_HK
dc.identifier.isiWOS:000084024500036-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridTsang, KWT=7201555024en_HK
dc.identifier.scopusauthoridChan, WM=7403918361en_HK
dc.identifier.scopusauthoridHo, PL=7402211363en_HK
dc.identifier.scopusauthoridChan, K=7406032228en_HK
dc.identifier.scopusauthoridLam, WK=7203021937en_HK
dc.identifier.scopusauthoridIp, MSM=7102423259en_HK
dc.customcontrol.immutablesml 130529-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats